A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(19 sites)

Australia

Research Site, Fitzroy

Research Site, St Albans

Research Site, Woolloongabba

Georgia

Research Site, Batumi

Research Site, Tbilisi

Poland

Research Site, Brzozów

Research Site, Koszalin

Research Site, Lublin

Research Site, Olsztyn

Research Site, Przemyśl

South Korea

Research Site, Seongnam-si

Research Site, Seoul

Taiwan

Research Site, Tainan

Research Site, Taipei

Research Site, Taoyuan District